Nabi Biopharmaceuticals Announces Results of First NicVAX Phase III Clinical Trial; Drug Did not Meet Primary Endpoint

Nabi Biopharmaceuticals NABI today announced that NicVAX did not meet its primary endpoint in the company's first of two confirmatory Phase III clinical trials. A preliminary assessment of the trial data showed that subjects treated with NicVAX quit smoking at a similar rate of approximately 11% compared to subjects who received placebo. As in previous trials, NicVAX was well-tolerated with a clinically acceptable safety and tolerability profile.